Baselga J, Cortes J, Kim SB, Im SA, Hegg R, Im YH, Roman L, Pedrini JL, Pienkowski T, Knott A, Clark E, Benyunes MC, Ross G, Swain SM
Notably, 77.1% achieved and maintained at least 5% weight loss over the full study period
Semaglutide : STEP 1 demonstrated 14.9% mean weight loss at 2.4 mg weekly over 68 weeks
Obstructive sleep apnea: current perspectives
Long Shelf Life: Product maintains quality for two years from manufacture date
Moreover, it lowers the risk of major cardiovascular events including heart attacks in some people